- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00509587
Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the antitumor activity of pazopanib, in terms of objective response rate (partial and complete response), in patients with recurrent or metastatic invasive breast cancer.
SECONDARY OBJECTIVES:
I. To determine the duration of objective response, rate and duration of stable disease.
II. To determine 6-month progression-free and median and overall survival rates in patients treated with this drug.
III. To document the safety and tolerability of this drug in these patients.
OUTLINE: This is a multicenter, open label study.
Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and at 1, 4, and 8 weeks for correlative laboratory studies. Blood samples are evaluated for the following tumor markers by ELISA: VEGF, bFGF, sFLT-1, sTIE-2, sE-Selectin, VCAM-1, PDGF-AA, PDGF-AB and PDGF-BB. TSP-1 in plasma is measured by Accucyte™ competitive immunoassay.
After completion of study treatment, patients are followed every 3 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA-Vancouver Cancer Centre
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria:
- No prior bevacizumab
- Histologically or cytologically confirmed invasive breast carcinoma (recurrent or metastatic disease)
- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan
- Patients who may still benefit from hormonal therapy are ineligible (patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression)
- Patients with HER-2 positive disease who have not yet received trastuzumab (Herceptin®) to maximal benefit are ineligible (patients with disease progression during trastuzumab therapy are eligible)
- No known brain metastases
- ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%
- Life expectancy > 12 weeks
- Absolute neutrophil count >= 1,500/mm³
- Platelets >=100,000/mm³
- Total bilirubin normal (exception made for patients with known Gilbert's disease)
- AST/ALT =< 2.5 times upper limit of normal (ULN)
- No proteinuria > +1 on two consecutive dipsticks taken >= 1 week apart
- PT/INR/PTT =< 1.2 times ULN
- No allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other study agents
- No QTc prolongation (defined as a QTc interval >= 500 msecs) or other significant ECG abnormalities
- No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or active peptic ulcer disease) that would impair ability to swallow and retain study drug
- No poorly controlled hypertension (systolic blood pressure [BP] >= 140 mm Hg or diastolic BP >= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior to study entry provided that the average of 3 BP readings prior to study entry is < 140/90 mm Hg
- No serious or non-healing wound, ulcer, or bone fracture
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 4 weeks
- No cerebrovascular accident within the last 6 months
- No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina within the last 12 weeks
- No venous thrombosis within the last 12 weeks
- No NYHA class III-IV heart failure Patients with a history of class II heart failure may be considered eligible provided they are asymptomatic on treatment
- No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery
- No cardiac angioplasty or stenting within the last 12 weeks
- No more than 1 prior chemotherapy regimen for recurrent disease
- No prior surgical procedures affecting absorption
- No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:
Therapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are allowed
No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:
- Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil
- Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or quinidine
- Immune modulators: cyclosporine, tacrolimus, or sirolimus
- Miscellaneous: theophylline, quetiapine, or risperidone
No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:
- Oral hypoglycemics: glipizide, glyburide, or tolbutamide
- Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or methylergonovine
- Neuroleptics: pimozide
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents
- No other concurrent anticancer therapy
- WBC >= 3,000/mm³
- No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease
- Creatinine normal OR creatinine clearance >= 60 mL/min
- At least 3 months since prior trastuzumab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (pazopanib hydrochloride)
Patients receive oral pazopanib once daily on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given orally
Other Names:
Correlative studies
Other Names:
Correlative studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Partial and Complete Response.
Time Frame: Up to 3 years
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT / MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Objective Response
Time Frame: From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
|
Duration of Stable Disease
Time Frame: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
Progression-free Survival
Time Frame: 6 months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions
|
6 months
|
Overall Survival
Time Frame: Up to 3 years
|
Computed using the Kaplan-Meier method.
|
Up to 3 years
|
Adverse Events Graded According to the NCI CTCAE Version 3.0
Time Frame: Up to 3 years
|
grade 3- 4 toxicities - transaminitis, hypertension, and neutropenia in three patients each (14% each) and grade 3 gastrointestinal hemorrhage in one patient (5%).
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Natasha Leighl, University Health Network-Princess Margaret Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2009-00199 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- N01CM62203 (U.S. NIH Grant/Contract)
- CDR0000557347
- PHL-057 (Other Identifier: University Health Network-Princess Margaret Hospital)
- 7638 (DUMC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on pazopanib hydrochloride
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Kidney Oncocytoma | Carcinoma of the Collecting Ducts of BelliniUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Sarcoma | Uterine CarcinosarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant MesotheliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedVon Hippel-Lindau SyndromeUnited States
-
National Cancer Institute (NCI)TerminatedParaganglioma | Metastatic Adrenal Gland Pheochromocytoma | Recurrent Adrenal Gland Pheochromocytoma | Extra-Adrenal ParagangliomaUnited States, Singapore, Hong Kong
-
Masonic Cancer Center, University of MinnesotaGlaxoSmithKlineTerminatedSarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Pancreatic Cancer | Lung Cancer | Colon Cancer | Hepatocellular CancerUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
Case Comprehensive Cancer CenterCompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedHigh Grade Sarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated... and other conditionsUnited States